Andy Mulvaney has 20+ years’ biopharma experience and has held executive leadership and board roles in public and private companies. He has an extensive track record of buy- and sell-side transactions, encompassing global out-licences, co-development deals, supply agreements, territorial carve-outs, acquisitions, divestments and company exits through IPO, with a particular emphasis on translation and commercialisation of early-stage university intellectual property. His current roles include interim CBO at Vesper Bio ApS, a Lundbeckfonden Biocapital company, and advisor and Non executive director to Quantum/AI company Kuano, Ltd.
Previously, Andy served as COO of a University of Oxford regenerative medicine spin out. Prior to that, Andy led global business development & licensing at Summit Therapeutics, Inc, a company he co-founded and which was publicly listed, first in London, and subsequently on NASDAQ (NASDAQ:SMMT). Andy was a postdoctoral fellow at the University of Oxford working on a novel ion-channel target for cardiac arrythmias in collaboration with Yamanouchi Pharmaceuticals Co. Ltd. (now Astellas).
He holds a PhD in organometallic chemistry from the University of Cardiff, where he was awarded a prestigious fully-funded studentship by open competition from the ICI Strategic Research Fund. He is a member of the Pharmaceutical Licensing Group and resides near Oxford, UK.